Biogen acquires rights for potential Actemra biosimilar; Royalty Pharma buys lumasiran royalty stream for up to $240M
Biogen has a new partner to help develop an experimental IL-6 biosimilar.
The Cambridge, MA-based company announced Thursday it has teamed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
